GenMark Diagnostics Company Profile (NASDAQ:GNMK)

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

GenMark Diagnostics, Inc. (NASDAQ:GNMK) posted its earnings results on Tuesday, May, 2nd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.02. The business had revenue of $12.54 million for the quarter, compared to analyst estimates of $12.55 million. GenMark Diagnostics had a negative return on equity of 146.00% and a negative net margin of 101.61%. View GenMark Diagnostics' Earnings History.

5 analysts have issued twelve-month price targets for GenMark Diagnostics' stock. Their predictions range from $13.00 to $17.00. On average, they expect GenMark Diagnostics' share price to reach $16.20 in the next year. View Analyst Ratings for GenMark Diagnostics.

Here are some recent quotes from research analysts about GenMark Diagnostics stock:

• 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (5/3/2017)
• 2. Needham & Company LLC analysts commented, "GNMK's 4Q16 revenue was consistent with its 1/10/17 preannouncement while its EPS was in line with consensus. Management provided initial 2017 revenue guidance that bracketed consensus. As previously disclosed on 1/10/17, GNMK ended 2016 with more than 55 customer agreements for over 85 ePlex instruments which seems to bode well for ePlex demand. GNMK announced that it submitted its ePlex 510(k) to the FDA on 12/22/16 and noted that it expects to obtain CE Marks for its three blood culture panels in 2Q17. With the European ePlex launch underway and the U.S. ePlex launch set for mid-2017, we reiterate our Buy rating since we expect ePlex to drive a significant acceleration in revenue growth." (3/1/2017)

Some companies that are related to GenMark Diagnostics include ABAXIS (ABAX), Natus Medical Incorporated (BABY), Luminex Corporation (LMNX), Quidel Corporation (QDEL), Mazor Robotics (MZOR), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Viveve Medical (VIVE), Alliance HealthCare Services (AIQ), FULGENT GENETIC (FLGT), Cytosorbents Corporation (CTSO), Neovasc (NVCN), IRIDEX Corporation (IRIX), Cogentix Medical (CGNT) and EDAP TMS S.A. (EDAP).

GenMark Diagnostics' management team includes the folowing people:

• James Charles Fox Ph.D., Independent Chairman of the Board
• Hany Massarany, President, Chief Executive Officer, Director
• Scott Mendel, Chief Financial Officer
• Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development, Chief Scientific Officer
• Eric Stier, Senior Vice President, General Counsel, Secretary
• Jennifer Anne Williams, Senior Vice President - Human Resources
• Michael W Gleeson, Senior Vice President, North American Commercial Operations
• Michael S Kagnoff, Director
• Daryl Jay Faulkner, Independent Director
• Lisa M. Giles, Independent Director

GenMark Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), JPMorgan Chase & Co. (7.51%), Jennison Associates LLC (6.59%), HighTower Advisors LLC (4.45%), Vanguard Group Inc. (4.16%) and Artisan Partners Limited Partnership (3.82%). Company insiders that own GenMark Diagnostics stock include Daryl Faulkner, Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.

GenMark Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Jennison Associates LLC, Artisan Partners Limited Partnership, Credit Suisse AG, TIAA CREF Investment Management LLC, Stoneridge Investment Partners LLC, Alliancebernstein L.P. and California Public Employees Retirement System. Company insiders that have sold GenMark Diagnostics stock in the last year include Eric Stier, Hany Massarany, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.

GenMark Diagnostics' stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Bellevue Group AG, Northpointe Capital LLC, JPMorgan Chase & Co., FMR LLC, Vanguard Group Inc., Schwab Charles Investment Management Inc. and Goldman Sachs Group Inc.. Company insiders that have bought GenMark Diagnostics stock in the last two years include Daryl Faulkner, Lisa M Giles, Michael Kagnoff and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.

Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GenMark Diagnostics stock can currently be purchased for approximately $12.59.